Leukotriene Modifiers Market Report 2026

Leukotriene Modifiers Market Overview

• Leukotriene Modifiers market size has reached to $23.54 billion in 2025 • Expected to grow to $30.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: The Rising Incidence Of Asthma And Allergic Conditions Drives Growth In The Leukotriene Modifier Market • Market Trend: Expansion Of Leukotriene Modifiers Market With Generic And Extended-Release Formulations Boosts Asthma Management • North America was the largest region in 2025.

What Is Covered Under Leukotriene Modifiers Market?

Leukotriene modifiers refer to a class of medications used to manage and treat allergic rhinitis (hay fever) and asthma. They work by blocking the action or production of leukotrienes, which are chemicals in the body that contribute to inflammation, bronchoconstriction (narrowing of the airways), and mucus production associated with these conditions. By inhibiting leukotrienes, these medications help reduce symptoms such as wheezing, shortness of breath, and nasal congestion. The main drug types of leukotriene modifiers include montelukast, zafirlukast, zileuton er, and zileuton. Montelukast is a leukotriene receptor antagonist used to prevent and manage asthma and to relieve symptoms of seasonal allergies. The forms are categorized into tablets, chewable tablets, and oral granules distributed through channels such as hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

What Is The Leukotriene Modifiers Market Growth Forecast?

The leukotriene modifiers market size is expected to see strong growth in the next few years. It will grow to $30.63 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to rising global burden of respiratory and allergic diseases, increasing diagnosis rates of asthma and rhinitis, growing demand for convenient oral therapies, expansion of generic drug penetration, improved access to respiratory care in emerging markets. Major trends in the forecast period include sustained use of leukotriene modifiers in asthma maintenance therapy, growing preference for oral and pediatric-friendly formulations, increasing role of leukotriene modifiers in allergic rhinitis management, widespread availability of generic leukotriene modifier drugs, use of leukotriene modifiers as add-on therapy with inhaled corticosteroids.

What Is The Driver Of The Leukotriene Modifiers Market?

The increasing incidence of asthma and allergic conditions is expected to propel the growth of the leukotriene modifier market going forward. Asthma and allergic conditions refer to disorders where the immune system overreacts to allergens, causing inflammation, airway constriction, and other respiratory symptoms. The incidence of asthma and allergic conditions is rising due to increased exposure to pollutants, rising temperatures, changing weather patterns, and higher population densities. The leukotriene modifier market supports respiratory health by providing therapies that reduce inflammation, improve airway function, and help manage symptoms of asthma and allergic conditions. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, in 2023, Australia recorded a total of 474 asthma-related deaths, comprising 325 females and 149 males. This figure is almost identical to the 473 asthma-related deaths reported in 2022, highlighting a consistent trend in asthma mortality over the two years. Therefore, the increasing incidence of asthma and allergic conditions is driving the growth of the leukotriene modifier industry.

Key Players In The Global Leukotriene Modifiers Market

Major companies operating in the leukotriene modifiers market are Merck And Co., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Limited, Sun Pharmaceutical Industries, Sumitomo Dainippon Pharma, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories, Apotex Pharmaceutical Holdings Inc., Torrent Pharmaceuticals Ltd., DAVA Pharmaceuticals, Alembic Pharmaceuticals Ltd., Lannett Company, Accord Healthcare, Jubilant Life Sciences Ltd., Aytu BioScience

Global Leukotriene Modifiers Market Trends and Insights

Major companies operating in the leukotriene modifier market are focusing on developing generic extended-release (ER) formulations to expand treatment options, improve dosing convenience, and meet growing patient demand for long-acting respiratory therapies. Generic extended-release tablets refer to pharmaceutical formulations designed to gradually release the active ingredient over an extended period, helping maintain consistent therapeutic levels, reduce dosing frequency, and enhance patient adherence compared to immediate-release versions. For instance, in April 2023, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, added Zileuton ER Tablets to its portfolio, offering a 600 mg extended-release formulation indicated for the prophylaxis and chronic management of asthma in adults and adolescents aged 12 years and older, providing sustained therapeutic coverage while supporting continued use during acute asthma exacerbations.

What Are Latest Mergers And Acquisitions In The Leukotriene Modifiers Market?

In April 2023, SK Capital Partners LP., a US-based private investment firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. This acquisition strengthens SK Capital’s pharmaceutical portfolio by leveraging Apotex’s extensive generic product range, international market presence, and experienced workforce to drive growth and operational expansion. It further enhances SK Capital’s ability to scale high-demand therapeutic categories by integrating Apotex’s established manufacturing capabilities, including its production of leukotriene modifiers such as montelukast drugs. Apotex Pharmaceutical Holdings Inc. is a Canada-based pharmaceutical company that manufactures leukotriene modifiers such as montelukast drugs.

What Defines the Leukotriene Modifiers Market?

The leukotriene modifiers market consists of sales of modafinil, armodafinil, amphetamine-based stimulants, fluoxetine, and sertraline. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leukotriene Modifiers Market Report 2026?

The leukotriene modifiers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leukotriene modifiers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.